Lifecore Biomedical, Inc. (LFCR)
NASDAQ: LFCR · Real-Time Price · USD
4.790
+0.020 (0.42%)
At close: May 8, 2026, 4:00 PM EDT
4.600
-0.190 (-3.97%)
After-hours: May 8, 2026, 7:43 PM EDT
Lifecore Biomedical Revenue
Lifecore Biomedical had revenue of $23.19M in the quarter ending March 31, 2026, a decrease of -34.02%. This brings the company's revenue in the last twelve months to $127.36M, down -2.27% year-over-year. In the fiscal year ending May 25, 2025, Lifecore Biomedical had annual revenue of $128.87M with 0.47% growth.
Revenue (ttm)
$127.36M
Revenue Growth
-2.27%
P/S Ratio
1.39
Revenue / Employee
$338,913
Employees
382
Market Cap
179.67M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| May 25, 2025 | 128.87M | 606.00K | 0.47% |
| May 26, 2024 | 128.26M | 24.99M | 24.20% |
| May 28, 2023 | 103.27M | -8.00M | -7.19% |
| May 29, 2022 | 111.27M | 10.40M | 10.31% |
| May 30, 2021 | 100.87M | -59.19M | -36.98% |
| May 31, 2020 | 160.07M | -397.49M | -71.29% |
| May 26, 2019 | 557.56M | 33.33M | 6.36% |
| May 27, 2018 | 524.23M | 54.45M | 11.59% |
| May 28, 2017 | 469.78M | -7.14M | -1.50% |
| May 29, 2016 | 476.92M | -62.34M | -11.56% |
| May 31, 2015 | 539.26M | 62.44M | 13.10% |
| May 25, 2014 | 476.81M | 35.11M | 7.95% |
| May 26, 2013 | 441.71M | 124.16M | 39.10% |
| May 27, 2012 | 317.55M | 40.82M | 14.75% |
| May 29, 2011 | 276.73M | 44.64M | 19.23% |
| May 30, 2010 | 232.09M | 3.54M | 1.55% |
| May 31, 2009 | 228.55M | -2.64M | -1.14% |
| May 25, 2008 | 231.19M | 25.76M | 12.54% |
| May 27, 2007 | 205.43M | -23.70M | -10.34% |
| May 28, 2006 | 229.13M | 24.41M | 11.92% |
| May 29, 2005 | 204.72M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Organogenesis Holdings | 514.70M |
| Aurora Cannabis | 272.13M |
| Akebia Therapeutics | 232.40M |
| Organigram Global | 204.21M |
| Anika Therapeutics | 116.26M |
| Assertio Holdings | 102.16M |
| SIGA Technologies | 93.78M |
| Journey Medical | 61.86M |
LFCR News
- 2 days ago - Lifecore reports Q1 EPS (43c), consensus (29c) - TheFly
- 3 days ago - Lifecore Biomedical Earnings Call Transcript: Q1 2026 - Transcripts
- 3 days ago - Lifecore Biomedical Reports Financial Results for the First Quarter Ended March 31, 2026, and Provides Corporate Update - GlobeNewsWire
- 10 days ago - Lifecore Biomedical to Report Financial Results for the First Quarter Ended March 31, 2026, on May 6, 2026 - GlobeNewsWire
- 10 days ago - Lifecore price target raised to $6 from $5.50 at Barrington - TheFly
- 17 days ago - Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Lifecore Biomedical to Participate at 12th Annual American Biomanufacturing Summit - GlobeNewsWire
- 6 weeks ago - Lifecore signs two CDMO service agreements with biopharmaceutical customer - TheFly